Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

5.27USD
2:19pm EST
Change (% chg)

$-0.05 (-0.94%)
Prev Close
$5.32
Open
$5.32
Day's High
$5.33
Day's Low
$5.07
Volume
419,738
Avg. Vol
717,129
52-wk High
$9.83
52-wk Low
$4.41

FOLD.OQ

Chart for FOLD.OQ

About

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $757.18
Shares Outstanding(Mil.): 142.33
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 29.51 30.38
EPS (TTM): -1.42 -- --
ROI: -20.67 15.44 14.86
ROE: -51.53 16.62 16.28

BRIEF-Amicus Therapeutics expects 2017 net operating cash flow of $175 - $200 mln

* Company expects full-year 2017 net operating cash flow of between $175 million to $200 million

Jan 09 2017

BRIEF-Amicus Therapeutics sees full-year 2017 net operating cash flow of $175 mln-$200 mln

* Amicus Therapeutics provides full-year 2017 strategic outlook and financial guidance

Jan 09 2017

BRIEF-Amicus Therapeutics Q3 loss per share $0.33

* Amicus Therapeutics announces third quarter 2016 financial results and corporate updates

Nov 07 2016

BRIEF-Amicus Therapeutics sees updates on drug for fabry's disease in Q4 2016 - SEC Filing

* Says U.S. Regulatory update related to its drug for fabry's disease anticipated in Q4 2016 - SEC Filing

Sep 07 2016

BRIEF-Amicus Therapeutics Q2 loss per share $0.40

* Amicus therapeutics announces second quarter 2016 financial results and corporate updates

Aug 09 2016

BRIEF-Amicus plans to submit Japanese new drug application for Migalastat

* Plans to submit a Japanese new drug application (J-NDA) to request marketing authorization for Migalastat in first half of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 03 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €74.84 -0.78
Shire PLC (SHP.L) 4,320.00 -73.00
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.S) CHF230.60 +7.50

Earnings vs. Estimates